Under the agreement, the companies plan to develop a customized solution that can be widely deployed for DNA sequencing.
The UK-based noninvasive prenatal testing firm also said that it has raised £2.5 million in funding through a share subscription.
The company is now seeking commercial partners in Brazil to make the Iona test available in the country.
Premaitha had been sued by Illumina for allegedly infringing on five patents related to noninvasive prenatal testing with its Iona test.
Premaitha entered into a secured loan facility agreement with Thermo Fisher, which is secured on the shares of Premaitha's Taiwanese subsidiary, Yourgene Bioscience.
Illumina had filed a series of suits against several companies in the UK starting in 2015, which were recently consolidated into one case.
Ampath will be one of the first laboratories in South Africa to offer a CE-IVD accredited noninvasive prenatal testing center and will act as a hub for such services.
Illumina has filed a new lawsuit against Premaitha, claiming it infringes on an Illumina patent related to noninvasive prenatal testing.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.
In Science this week: research regulation and reporting requirement reform, and more.
With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.